|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||0.0784 - 0.0784|
|52-week range||0.0784 - 0.0784|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results and will now advance to the next stage of development in patients. In a study of healthy volunteers led by renowned surgeon Prof Fiona Wood AM the Pharmaxis drug demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the second of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The increase in dose lead to a predictable increase in drug blood levels in patients and showed the same good tolerability seen in the first dose cohort.